Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease
dc.contributor.author | Taşçı, Elif Şenocak | |
dc.contributor.author | Bahçebaşı, Zerrin Bicik | |
dc.date.accessioned | 2020-04-30T23:31:45Z | |
dc.date.available | 2020-04-30T23:31:45Z | |
dc.date.issued | 2015 | |
dc.department | DÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.description | WOS: 000363832600010 | en_US |
dc.description | PubMed: 26338166 | en_US |
dc.description.abstract | Fabry disease, an X-linked lysosomal storage disorder, is caused by alpha-galactosidase A deficiency and leads to accumulation of glycospinhgolipids in most tissues, with life-theratening consequences in the kidney, heart, and cerebrovascular system. Enzyme replacement therapy is available as 2 different preparations: agalsidase alfa and agalsidase beta. Enzyme replacement therapy is started as soon as the diagnosis is confirmed, but there is no data available in the literature about its safety during preganacy. Herein, we described 2 patients with Fabry disease who received agalsidase beta during their pregnancy. This report is important as the data about enzyme replacement therapy during pregnancy is restricted with case reports. | en_US |
dc.identifier.endpage | 408 | en_US |
dc.identifier.issn | 1735-8582 | |
dc.identifier.issn | 1735-8604 | |
dc.identifier.issue | 5 | en_US |
dc.identifier.startpage | 406 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12684/4452 | |
dc.identifier.volume | 9 | en_US |
dc.identifier.wos | WOS:000363832600010 | en_US |
dc.identifier.wosquality | Q4 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Iranian Soc Nephrolgy | en_US |
dc.relation.ispartof | Iranian Journal Of Kidney Diseases | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Fabry disease | en_US |
dc.subject | pregnancy | en_US |
dc.subject | agalsidase beta | en_US |
dc.subject | enzyme replacement | en_US |
dc.title | Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease | en_US |
dc.type | Article | en_US |
Dosyalar
Orijinal paket
1 - 1 / 1
Küçük Resim Yok
- İsim:
- 4452.pdf
- Boyut:
- 1.2 MB
- Biçim:
- Adobe Portable Document Format
- Açıklama:
- Tam Metin / Full Text